Cancers & treatments·Regimen libraryConsolidation

Chemoradiation then durvalumab (PACIFIC)

Checked 2026-09-09

Unresectable stage III NSCLC without progression after platinum-based chemoradiation

One cycle

every 28 days × 12 · about 48 weeks in total

28-day cycle × 12 months of durvalumab (about 48 weeks)Intravenous

Components

Drug	Dose	Route	Days	Note
Durvalumab Monoclonal antibody (anti-PD-L1)	10 mg/kg every 2 weeks or 1,500 mg every 4 weeks	IV	D1

Cycles

12 months of durvalumab

28-day cycle

Emetogenicity

Minimal (<10%)

G-CSF

Not routine

Notes

Start within 42 days of the last radiotherapy fraction; pneumonitis risk is additive with radiation.

Used in

Non-small-cell lung cancer

Trials

PACIFIC

Products

Durvalumab

Source

PACIFIC, NEJM 2017

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.